Person:
ELLERGEZEN, PINAR

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Organizational Unit

Job Title

Last Name

ELLERGEZEN

First Name

PINAR

Name

Search Results

Now showing 1 - 4 of 4
  • Publication
    Effect of storage period of erythrocyte suspensions on the CD4 & CD8 T cells
    (Wiley, 2021-08-01) Bal, Salih Haldun; Kumaş, Levent Tufan; Cevhertaş, Laçin; Yılmaz, İzel; Ellergezen, Pınar Hız; Budak, Ferah; Heper, Yasemin; Göral, Güher; Oral, Haluk Barbaros; BAL, SALİH HALDUN; Kumaş, Levent Tufan; Cevhertaş, Laçin; Yılmaz, İzel; ELLERGEZEN, PINAR; BUDAK, FERAH; HEPER, YASEMİN; Göral, Güher; ORAL, HALUK BARBAROS; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dr. Rasit Durusoy Kan Bankası.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Sağlık Bilimleri Enstitüsü/Mikrobiyoloji-İmmünoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Klinik Mikrobiyoloji Anabilim Dalı.; 0000-0003-2287-3569; 0000-0001-7625-9148; 0000-0003-0463-6818; F-4657-2014; IZP-9398-2023; K-7285-2012; JSK-9450-2023; KBR-5535-2024; FHB-1791-2022; FYD-1431-2022; CPH-1647-2022; CTY-9474-2022; JGX-8396-2023
  • Publication
    Evaluation of the relationship between proinflammatory cytokine levels and clinical findings of fibromyalgia syndrome
    (Shiraz Inst Cancer Res, 2021-01-01) Ellergezen, Pınar; Alp, Alev; Çavun, Sinan; ELLERGEZEN, PINAR; ALP, ALEV; ÇAVUN, SİNAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Farmakoloji Anabilim Dalı; AAC-9702-2019; ICM-4005-2023; EKZ-2544-2022
    Background: Immune system has an important effect on pain related disorders such as fibromyalgia syndrome (FMS). There is no specific laboratory technique for the diagnosis of FMS, but measuring serum proinflammatory cytokines may help. Objective: The purpose of our study was to determine the serum levels of immune mediators and their relationship with FMS symptoms. Methods: 25 healthy individuals and 29 FMS patients receiving pregabalin 150 mg/day for a minimum of 3 months were included in this study. FMS patients were diagnosed according to diagnostic criteria of the American College of Rheumatology (ACR 2010). Widespread pain index (WSI), fatigue, waking unrefreshed, cognitive symptoms, somatic symptoms, and Fibromyalgia Impact Questionnaire (FIQ) scores were evaluated in patients with FMS. Serum levels of proinflammatory cytokines (IL-2, IL-6, IL 12, IL-17, IFN-gamma, TNF-alpha) were assessed using enzyme-linked immunosorbent assay (ELISA). Results: Proinflammatory cytokine levels were higher in the control group than patients with FMS (P<0.05). A positive correlation was found between age and WSI (P=0.037). In addition, a significant positive relationship was determined between IL-17 level and waking unrefreshed (P=0.049). There was no significant relationship between other cytokines and clinical findings. Conclusion: Lower proinflammatory cytokine levels identified in FMS patients may be related to pregabalin treatment, and there may be an impairment in the inflammatory response. On the contrary, IL-17 showed positive correlation with waking unrefreshed.
  • Publication
    Pregabalin inhibits proinflammatory cytokine release in patients with fibromyalgia syndrome
    (Turkish League Against Rheumatism, 2023-06-01) Ellergezen, Pınar; ALP, ALEV; ELLERGEZEN, PINAR; ÇAVUN, SİNAN; Çavun, Sinan; Çelebi, Melih; ÇELEBİ, MELİH; Macunluoğlu, Aslı Ceren; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Farmakoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Fizik Tedavi ve Rehabilitasyon Anabilim Dalı.; 0000-0002-6802-5998; AAC-9702-2019; JFJ-7690-2023
    Objectives: The main goal of the study was to investigate how pregabalin (PGB) affects proinflammatory cytokine release in patients with fibromyalgia syndrome (FMS).Patients and methods: This experimental research study was conducted with 85 female participants (mean age: 49.6 & PLUSMN;10.1 years; range, 30 to 73 years) between April 2020 and November 2020. Of the participants, 30 were FMS patients using PGB 150 mg/day for at least three months, 30 were FMS patients not using PGB, and 25 were healthy individuals. The detection of FMS was carried out according to the 2010 American College of Rheumatology diagnostic criteria. Levels of proinflammatory cytokines (interleukin [IL]-2, IL-6, IL-12, IL-17, interferon-gamma, and tumor necrosis factor-alpha) were measured by enzyme-linked immunosorbent assay.Results: Serum concentrations of proinflammatory cytokines were remarkably decreased in FMS patients using PGB (p<0.001) and were higher in patients with FMS not using PGB than in healthy subjects (p<0.001). The highest values of proinflammatory cytokines were found in the group of FMS patients not using PGB (p<0.001).Conclusion:These results indicate that PGB inhibits the release of proinflammatory cytokines, suggesting that it can be used as an anti-inflammatory agent in inflammatory cases.
  • Publication
    Evaluation of the potential roles of activin-A, activin-B, and follistatin molecules exhibiting immunomodulatory properties in brucellosis
    (Wiley, 2021-08-01) Kızmaz, Muhammed Ali; Ellergezen, Pınar Hız; Demir, Nesrin; Çağan, Eren; Akalın, Emin Halis; Oral, Haluk Barbaros; Budak, Ferah; Kızmaz, Muhammed Ali; ELLERGEZEN, PINAR; AKALIN, EMİN HALİS; ORAL, HALUK BARBAROS; BUDAK, FERAH; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları Anabilim Dalı.; 0000-0001-5334-7911; 0000-0001-7530-1279; 0000-0003-0463-6818; 0000-0001-7625-9148; AAU-8952-2020; F-4657-2014; K-7285-2012; HKN-2347-2023; IZP-9398-2023